Galmed announces positive results of phase 1 study of amilo-5mer

Tel aviv, israel, jan. 10, 2022 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a phase 1 clinical trial of amilo-5mer in healthy volunteers that demonstrated an excellent safety profile and tolerability.
GLMD Ratings Summary
GLMD Quant Ranking